It’s Beyond The Food: Non-Diet Health Coaching

Nobody screens you for disordered eating before prescribing a GLP-1. That is not an accident. It is a gap in the entire informed consent process, and it is the subject of this conversation.I talk with Dr. Michelle Tubman, an emergency physician, about what informed consent for GLP-1 medications should actually include and rarely does.In this episode you will learn:What Michelle sees in the emergency room after patients start GLP-1 medicationsWhy most people never connect their symptoms back to the medicationWhat the two-year Ozempic study actually found about weight regainWhy disordered eating screening is not required before a GLP-1 prescriptionWhat true informed consent would require, modeled on how oncologists handle chemotherapyMentioned in the show:Beyond GLP-1 Expert Podcast Series: https://program.stephaniedodier.com/beyond-glp-1Dr. Michelle Tubman Community: http://enough.wayzhealth.comDr. Michelle Tubman on Instagram: https://www.instagram.com/wayzahealth/Coach Corner Vault: https://www.stephaniedodier.com/coach-corner/Non-Diet Client Assessment Tool: https://www.stephaniedodier.com/clientassessmentNon-Diet Coaching Certification Waitlist: https://www.stephaniedodier.com/non-diet-coaching-certification/Groundwork Waitlist: https://www.stephaniedodier.com/groundwork

The Ozempic era did not create weight stigma. It just showed us how shallow the acceptance always was.Dr. Angela Meadows is a social psychologist, weight stigma researcher, and founder of the International Weight Stigma Conference. She has spent her career studying how weight stigma operates at the individual, relational, and systemic level. In this conversation, she brings her research lens directly to the GLP-1 moment.This is the conversation mainstream health is not having.In this episode, you'll learn:Social identity theory — why the GLP-1 era exposed what body positivity was always missingWhat weight stigma actually is at the structural level, and why interpersonal niceness cannot fix a systemic problemThe public health data on GLP-1 that is buried in supplementary materials and not being readHow medicalized weight stigma is shifting — and why refusing GLP-1 is becoming its own form of clinical targetWhether it is possible to live in this culture and not internalize weight stigma, and what intentional protection requiresMentioned in the show:Beyond GLP-1 Expert Podcast Series: https://program.stephaniedodier.com/beyond-glp-1International Weight Stigma Conference: https://weightstigmaconference.com/GLP-1 Informed Consent Resource — Size Inclusive Medicine: https://sizeinclusivemedicine.org/wp-content/uploads/2023/11/MSSI-GLP1-Informed-Consent-1-1.pdfRelated episode — Beyond GLP-1 with Ragen Chastain: https://www.stephaniedodier.com/episodes/glp-1-science-research-weight-loss/Coach Corner Vault: https://www.stephaniedodier.com/coach-corner/Non-Diet Client Assessment Tool: https://www.stephaniedodier.com/clientassessmentNon-Diet Coaching Certification Waitlist: https://www.stephaniedodier.com/non-diet-coaching-certification/Groundwork Waitlist: https://www.stephaniedodier.com/groundwork

GLP-1 medications are being prescribed with no eating disorder screening and no monitoring. What could go wrong? According to eating disorder specialist and registered dietitian Marci Evans, quite a lot.Marci has spent her career at the intersection of body image and eating disorder care. In this conversation, she shares what she is actually seeing in her clinical practice and why it frightens her.What you will learn in this episode:Why weight loss does not reliably improve body image, even for people who want itHow GLP-1 medications can fuel and accelerate existing eating disorder behaviorsWhy there is almost no research on GLP-1 and body image, and what that tells usWhat the absence of screening and monitoring means for eating disorder riskHow weight-neutral practitioners can hold space for clients on GLP-1 without abandoning their clinical ethicsMentioned in the show:Beyond GLP-1 Expert Podcast Series: https://program.stephaniedodier.com/beyond-glp-1Marci Evans Newsletter on her website: https://marcird.com/Marci Evans on Instagram: https://www.instagram.com/marcird/Research — GLP-1 and body image: https://pubmed.ncbi.nlm.nih.gov/40267815/Research — GLP-1 and binge eating disorder: https://pmc.ncbi.nlm.nih.gov/articles/PMC11156433/Coach Corner Vault: https://www.stephaniedodier.com/coach-corner/Non-Diet Client Assessment Tool: https://www.stephaniedodier.com/clientassessmentNon-Diet Coaching Certification Waitlist: https://www.stephaniedodier.com/non-diet-coaching-certification/Groundwork Waitlist: https://www.stephaniedodier.com/groundwork

The science on GLP-1 drugs is not what the marketing says it is.Ragen Chastain has been studying weight science, weight stigma, and healthcare practice for over 20 years. In this episode, she gives us the clearest breakdown yet of what the research actually supports — as of May 2026 — and how to tell the difference between evidence and pharmaceutical strategy.This is part of the Beyond GLP-1 expert interview series on It's Beyond The Food.What you'll learn in this episode:Why GLP-1 drugs are solid for type 2 diabetes but how the weight loss dose is a fundamentally different useWhat the weight regain data actually shows — including what happens while people are still on the drugHow secondary use claims get built and why the cardiovascular trial results apply to far fewer people than the approval suggestsWhat the death data shows — and why Novo Nordisk was cited for under-reporting serious adverse eventsSpecific questions to ask your provider before starting a GLP-1 medication — and how to ask for weight-inclusive careMentioned in the show:Beyond GLP-1 Expert Podcast Series: https://program.stephaniedodier.com/beyond-glp-1Ragen Chastain's Weight and Healthcare Substack: https://weightandhealthcare.substack.com/Dances With Fat: https://danceswithfat.org/Ragen's speaking website — Sized for Success: https://www.sizedforsuccess.com/Dr. Rachel Fox's anti-obesity assemblage dissertation: https://www.rachelefox.com/research.htmlGLP-1 Informed Consent (Medical Students for Size Inclusivity, 2023): https://sizeinclusivemedicine.org/wp-content/uploads/2023/11/MSSI-GLP1-Informed-Consent-1-1.pdfLouise Adams on GLP-1 — listen to the earlier episode in the Beyond GLP-1 series: https://podcasts.apple.com/ph/podcast/468-beyond-glp-1-a-triumph-of-marketing-over/id1172102796?i=1000766587046

GLP-1s did not just change medicine. They changed a movement.Virgie Tovar is a weight stigma expert, activist, and journalist who has been watching this unfold from a perspective most voices in this conversation don't have. In this episode, she traces exactly what happened to body positivity and fat activism when Ozempic entered the room, and she does not soften the analysis.In this episode:The real difference between body positivity and fat activism, and why that distinction has never mattered moreHow body autonomy became a political shield for choices that carry collective consequencesWhat "lab coat washing" means, and how GLP-1 marketing uses it to disguise a financial machine as a health interventionWhy GLP-1s work through starvation states, and what that does to desire, mood, and the capacity to resistThe intergenerational fallout Stephanie is already seeing coming in the next wave of clientsMentioned in the show:Beyond GLP-1 Expert Podcast Series: https://program.stephaniedodier.com/beyond-glp-1Virgie Tovar's Substack: http://virgietovar.substack.comVirgie Tovar's Instagram: http://www.instagram.com/virgietovarVirgie Tovar's GLP-1 Truth Serum Podcast: https://open.spotify.com/show/1t00VeiyyzD7ITDxjDzGnCCoach Corner Vault: https://www.stephaniedodier.com/coach-corner/Non-Diet Client Assessment Tool: https://www.stephaniedodier.com/clientassessmentNon-Diet Coaching Certification Waitlist: https://www.stephaniedodier.com/non-diet-coaching-certification/Groundwork Waitlist: https://www.stephaniedodier.com/groundwork

The drugs have been sold as a miracle. The science has been quietly shaped by the companies profiting from them. And the deaths are not yet being called a scandal.Clinical psychologist Louise Adams co-authored a paper that has already been read more than 7,500 times in its first ten days. She joins me to trace the three-pronged pharmaceutical marketing strategy behind GLP-1 drugs, follow the money through conflict-of-interest research, celebrity spokespeople, and government lobbying, and tell us what real informed consent would actually require.In this episode you will learn:The 2015 Novo Nordisk marketing roadmap that predicted everything we are living through nowWhy many obesity researchers are now functioning as pharmaceutical sales representativesWhat weight cycling is and why it is missing from the GLP-1 conversationWhat a health professional's informed consent process should look likeWhy Louise is cautiously optimistic that GLP-1 research will inadvertently strengthen the case for weight inclusive medicine in the next decadEMentioned in the show: Listen to the entire Beyond GLP-1 podcast series: https://program.stephaniedodier.com/beyond-glp-1Louise Adams' paper: GLP-1 medication for weight loss, a triumph of marketing over patient care -- https://www.tandfonline.com/doi/full/10.1080/21604851.2026.2646492Louise Adams -- meet Louise and her work: https://untrapped.com.au/meet-louise/Louise Adams' newsletter and podcast All Fired Up: untrapped.com.auRagen Chastain's Weight and Healthcare Substack: weightandhealthcare.substack.comAWIM GLP-1 Informed Consent document: https://sizeinclusivemedicine.org/wp-content/uploads/2023/11/MSSI-GLP1-Informed-Consent-1-1.pdfHAES Health Sheets: https://haeshealthsheets.com/Non-Diet Coaching Assessment Tool: stephaniedodier.com/clientassessmentThe Groundwork waitlist: https://program.stephaniedodier.com/groundwork